BridgeBio Q2 FY26 net loss narrows to $152.2 million; revenue rises 120.37% to $243.7 million

• BridgeBio posted Q2 revenue of $243.7 million, more than doubled from a year earlier, driven by $222.4 million in U.S. Attruby net product revenue.
• Net loss attributable to common stockholders narrowed to $152.2 million, or $0.78 per share, from $181.9 million, or $0.95 per share.
• Total operating costs and expenses climbed 43.3% to $350.8 million on higher SG&A and R&D spending, while other expense was $48.8 million.
• Cash, cash equivalents, and marketable securities rose to $720.2 million at June 30, excluding a $1 billion preferred equity financing that closed July 1.
• FDA accepted Priority Review NDAs for BBP-418 (PDUFA Nov. 27, 2026) and encaleret (PDUFA May 8, 2027); oral infigratinib NDA was submitted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101601PRIMZONEFULLFEED9807111) on August 10, 2026, and is solely responsible for the information contained therein.